Fosun buys GSK plant, hepatitis B drug rights

July 9, 2019

Fosun Pharmaceutical has announced plans for its subsidiary to spend up to $36 million to buy GlaxoSmithKline's Suzhou pharmaceutical factory in east China.

YaoPharma, Fosun's Chongqing unit, will not only acquire GSK's production facilities but also the rights to its chronic hepatitis B drug lamivudine.

Lamivudine is used in GSK’s HIV and hepatitis drug Epivir.

GSK has recently opened continuous manufacturing facilities in Singapore.

Read the Xinhua report